FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lowery Thomas J.
2. Issuer Name and Ticker or Trading Symbol

T2 Biosystems, Inc. [ TTOO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Scientific Officer
(Last)          (First)          (Middle)

101 HARTWELL AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

3/14/2020
(Street)

LEXINGTON, MA 02421
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $0.395 3/14/2020  A   180000     (1)3/14/2030 Common Stock 180000 $0.00 180000 D  
Restricted Stock Units  (2)3/14/2020  A   90000     (3) (3)Common Stock 90000 $0.00 90000 D  

Explanation of Responses:
(1) The stock option vests in 48 equal monthly installments commencing March 14, 2020.
(2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
(3) The restricted stock units vest in three equal annual installments commencing March 14, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Lowery Thomas J.
101 HARTWELL AVENUE
LEXINGTON, MA 02421


Chief Scientific Officer

Signatures
/s/ John Sprague, Attorney-in-fact3/18/2020
**Signature of Reporting PersonDate

T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more T2 Biosystems Charts.
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more T2 Biosystems Charts.